Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of clonidine, ketamine, and magnesium sulfate used primarily for pain management, particularly for neuropathic pain. This combination leverages synergistic effects between the three medications to enhance analgesic efficacy while potentially reducing side effects. ## Mechanism of Action - **Ketamine** acts as an NMDA receptor antagonist, blocking pain transmission pathways - **Magnesium sulfate** functions as the body's natural NMDA receptor antagonist, binding to the receptor channel at rest and increasing ketamine's binding affinity for NMDA receptors - **Clonidine** works primarily as an alpha-2 adrenoceptor agonist, causing central hypotensive effects and decreasing transmission of pain signals at the spine The combination appears particularly effective because magnesium enhances ketamine's analgesic properties, while clonidine provides additional pain relief through a different mechanism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clonidine + ketamine + magnesium sulfate.